Understanding the origins of mutations in lung cancer
Official title: Cell-of-Origin Footprints of Passenger Mutations in Human Lung Cancer
Funded at New York University School of Medicine · NIH-10916571 · Data updated 2026-11-12
This study is looking at the different types of normal cells that can turn into lung cancer, hoping to understand how these origins affect the way the cancer grows and how we can treat it better, so that doctors can create more personalized care for patients.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $484,128 |
| NIH project number | 5R37CA229861-04 |
| Project ID | NIH-10916571 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with lung adenocarcinoma who are seeking more effective treatment options.
✕Less likely to help
Patients with other types of lung cancer or those who are not diagnosed with cancer may not benefit from this research.
What this research studies
This research investigates the normal cell types from which lung adenocarcinomas arise, aiming to identify how these origins influence cancer development and treatment. By analyzing patterns of passenger mutations in tumors, the study seeks to uncover patient-specific signals that indicate the cell of origin for lung cancer. This approach addresses significant gaps in current knowledge, particularly the variability of cell origins among patients and the limitations of existing models. The findings could lead to improved prognostic tools and therapeutic strategies tailored to individual patients.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment options for lung cancer patients based on the specific origins of their tumors.
How similar studies have gone: While the approach of using passenger mutation patterns to identify cell origins has shown promise in preliminary studies, it has not been rigorously tested in lung cancer, making this research a novel endeavor.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Imielinski, Marcin — New York University School of Medicine
- Study coordinator: Imielinski, Marcin
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.